Innocare Pharma's Orelabrutinib Receives Marketing Authorization from Australian TGA

Stock News05-27

Innocare Pharma Limited (688428.SH) announced that it has received notification that orelabrutinib (marketed as Yinuokai® and HIBRUKA®) has been granted marketing authorization by the Australian Therapeutic Goods Administration (TGA). Orelabrutinib is a novel, highly selective BTK inhibitor independently developed by the company, designed to effectively minimize off-target effects and associated adverse reactions, thereby significantly enhancing treatment safety and efficacy. Previously, orelabrutinib has been approved in China for four indications: first-line chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), CLL/SLL in patients who have received at least one prior therapy, relapsed/refractory mantle cell lymphoma (r/r MCL) in patients who have received at least one prior therapy, and relapsed/refractory marginal zone lymphoma (r/r MZL) in patients who have received at least one prior therapy. All four indications are included in China's National Reimbursement Drug List. In the international market, orelabrutinib has also been approved in Singapore for the treatment of adult patients with r/r MCL and r/r MZL.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment